Universe Pharmaceuticals INC SEC filings document the disclosures of a Cayman Islands foreign private issuer operating a pharmaceutical production and distribution business in China. Form 6-K reports cover interim financial results, revenue and cost categories for company and third-party products, and current reports tied to governance and capital-structure matters.
The filing record also includes proxy materials and annual general meeting results, an equity incentive plan, and amendments related to ordinary-share structure, including Class A and Class B ordinary shares and authorized share capital. These filings describe shareholder voting matters, board and compensation arrangements, share-based awards and formal corporate actions affecting UPC securities.
Universe Pharmaceuticals INC reported that shareholders approved all eight proposals at its September 30, 2026 annual general meeting. Shareholders representing approximately 88.48% of the outstanding shares carrying voting rights were present in person or by proxy, and a quorum was present. As of August 31, 2026, the record date, 5,008,313 Class A ordinary shares and 16,077 Class B ordinary shares were issued and outstanding; each Class A share carried one vote and each Class B share carried 100 votes. All resolutions were voted on by poll.
Universe Pharmaceuticals INC (UPC) has filed a preliminary shelf registration for primary offerings of up to $200,000,000 in Class A ordinary shares, debt securities, warrants, rights and units, and resale by selling shareholders of 4,376,552 Class A ordinary shares, after effectiveness.
UPC receives no proceeds from resales and bears registration costs; sellers bear commissions and discounts. Primary-offering terms and net proceeds will appear in applicable supplements. While public float remains below $75 million, primary sales cannot exceed one-third of public float in any 12-month period. Resale shares equal 87.39% of 5,008,313 Class A shares issued and outstanding as of the prospectus date; UPC warns potential resales could depress the share price.
UPC is a Cayman Islands holding company whose operations are conducted through subsidiaries in China; investors hold parent shares, not direct interests in operating entities. For the six months ended March 31, 2026, revenue was $9,036,190 and net loss was $1,554,813. Class B shares carry 100 times the voting rights per share of Class A shares. The prospectus also describes PRC cash-transfer limits and regulatory risks.
Universe Pharmaceuticals INC (UPC) has amended a prior Form 6-K to include the full notice and proxy statement for its annual general meeting of shareholders. The meeting is scheduled for September 30, 2026 at 10:00 a.m. Beijing Time in Ji’an, Jiangxi, China, with a record date of August 31, 2026.
Shareholders will vote on eight proposals: re-election of five directors; a conditional 1-for-10 share consolidation of all Class A and Class B ordinary shares (effective on the 25th trading day after any 12‑month “Trigger Event” when the Nasdaq closing bid is below $1.00 for three consecutive trading days); adoption of an amended and restated memorandum of association to reflect the consolidation; and a proposal allowing adjournment of the meeting if more time is needed to secure votes. Each Class A share carries one vote, and each Class B share carries 100 votes, with 5,008,313 Class A and 16,077 Class B shares outstanding as of the record date. The board unanimously recommends voting “FOR” all proposals.
Universe Pharmaceuticals INC (UPC) reports that Star Voyage International Limited and its owner, Xuncheng Chen, together beneficially own 497,917 Class A ordinary shares, representing 9.94% of the Class A shares. This percentage is based on 5,008,313 Class A ordinary shares outstanding as of July 27, 2026. All reported voting and dispositive powers over these 497,917 shares are shared, with no sole voting or dispositive power reported for either Star Voyage International Limited or Xuncheng Chen.
Universe Pharmaceuticals INC (UPC) received a Schedule 13G reporting that August Luck Global Limited and Xuefeng Li together beneficially own 465,258 Class A ordinary shares. This represents 9.29% of the Class A ordinary shares, based on 5,008,313 shares outstanding as of July 27, 2026.
The 465,258 shares are held by August Luck Global Limited, a British Virgin Islands company that is wholly owned and controlled by Xuefeng Li of the People’s Republic of China. Both reporting persons disclose shared voting and dispositive power over these shares, with no sole voting or dispositive power.
Universe Pharmaceuticals INC (UPC) received a Schedule 13G reporting that Meridian Prosperous Limited and its sole owner, Shanshan Lu, beneficially own 498,922 Class A ordinary shares, representing 9.96% of the Class A shares outstanding. The shares are held by Meridian Prosperous Limited, with voting and dispositive power shared between the entity and Lu.
The reported ownership percentage is based on 5,008,313 Class A ordinary shares outstanding as of July 30, 2026. Meridian Prosperous Limited is organized in the British Virgin Islands, and Lu is a citizen of the People’s Republic of China.
Universe Pharmaceuticals INC (UPC) received a Schedule 13G reporting that Horizon Ridge Limited and its sole owner, Shan Xie, beneficially own 499,424 Class A ordinary shares. This represents 9.97% of the Class A ordinary shares, based on 5,008,313 shares outstanding as of July 27, 2026.
Both Horizon Ridge Limited and Shan Xie report shared voting and dispositive power over 499,424 shares and no sole voting or dispositive power. The filing reflects passive beneficial ownership, with a joint filing agreement attached as an exhibit.
Universe Pharmaceuticals INC (UPC) has a significant shareholder disclosure on Schedule 13G. Origin Force Intelligence Limited and its sole owner, Piao Ye, report beneficial ownership of 916,759 Class A ordinary shares, representing 18.30% of the Class A shares.
All voting and dispositive power over these 916,759 shares is reported as shared, with no sole voting or dispositive power. The percentage is calculated based on 5,008,313 Class A ordinary shares outstanding as of July 27, 2026.
Universe Pharmaceuticals INC (UPC) received a Schedule 13G reporting passive beneficial ownership of its Class A ordinary shares by Clever Way Global Limited and Lu Yang. The filing states that Clever Way Global Limited beneficially owns 498,922 Class A ordinary shares, all of which are also attributed to Lu Yang through ownership and control of Clever Way Global Limited. This position represents 9.96% of the Class A ordinary shares, based on 5,008,313 shares outstanding as of July 27, 2026. Voting and dispositive power over these shares is reported as shared, with no sole voting or dispositive power for either reporting person.